Go for three.

Efficacy Matters, Choose OMNI^®

Learn More

The Challenge

In eyes with primary open-angle glaucoma, identifying where blockage or resistance occurs within the conventional outflow pathway can be hard.

Targeting the trabecular meshwork alone, or isolating a single point, may not be enough to lower IOP.

75% of Surgeons want to address the conventional outflow pathway first ¹

Between 50-75% of resistance may be in the Trabecular Meshwork^2,3,4

Up to 50% of resistance may be in Schlemm’s canal and the distal collector channels^2,3,4

The Solution

OMNI^® targets all three points of resistance.

Trabecular meshwork
trabeculotomy

Schlemm’s canal
canaloplasty

Collector channels
canaloplasty

ONE MIGS device

TWO implant-free procedures

THREE points of resistance

Learn More

Meet the next generation OMNI^® Surgical System.

With the OMNI^® Surgical System, you can perform two implant-free procedures targeting three points of resistance with one intelligent device.

Two procedures in one
intelligently designed device.

The OMNI^® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

Canaloplasty

With its unique implant-free approach, the OMNI^® Surgical System lets you access Schlemm’s canal with the microcatheter through a single clear corneal incision. Intelligently engineered with an internal reservoir delivering a controlled amount of viscoelastic fluid.

Trabeculotomy

To address the trabecular meshwork as a point of resistance within the conventional outflow pathway, the OMNI^® Surgical System lets you perform a trabeculotomy according to your surgical plan.

Summary of Evidence

DEMONSTRATED IOP REDUCTION WHEN COMBINED WITH CATARACT SURGERY

TRABECULOTOMY AND CANALOPLASTY IN MILD/MODERATE/ADVANCED EYES WITH POAG^5,6

DEMONSTRATED IOP REDUCTION IN A STANDALONE PROCEDURE

TRABECULOTOMY AND CANALOPLASTY IN MILD/MODERATE EYES WITH POAG⁷

Reimbursement Information

Please download our Reimbursement Guide for OMNI^® Surgical System Reimbursement Information

Download

Upcoming Events

See Full list See Less list

News

March 09 , 2023

Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System

September 30 , 2022

Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting

April 20 , 2022

Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

March 24 , 2022

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI^® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

November 18 , 2021

Microinvasive Glaucoma Surgery with the OMNI® Surgical System is Associated with Diminished Diurnal IOP Fluctuations, a Significant, Independent Risk Factor for Glaucoma Progression

November 10 , 2021

Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG).

August 26 , 2021

Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference

August 24 , 2021

Sight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma

December 01 , 2020

Sight Sciences Announces Substantial Crossover Raise

July 14 , 2020

Sight Sciences Appoints Donald J. Zurbay to Company’s Board of Directors

June 25 , 2020

Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel Hires

March 30 , 2020

Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology

April 30 , 2019

Sight Sciences Announces Official Launches of TearCare^® and the Enhanced, Next Generation OMNI^® System

January 04 , 2018

Sight Sciences Expands Surgical Portfolio with FDA Clearance of the OMNI^™ Surgical System

Request more info about the OMNI^® Surgical System

Inquiry type*

Specialty*

First Name*

Last Name*

Email Address*

Phone Number*

City*

State*

Zip Code*

Information Requested*

Other Information Requested*

Referral source*

Interested in other Sight Sciences products?

TearCare® System

Submit

Important Product Information

OMNI^® Surgical System IMPORTANT PRODUCT INFORMATION

Indications for Use

The OMNI^® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

Contraindications

Do not use the OMNI^® in any situations where the iridocorneal angle is compromised or has been damaged (e.g., from trauma or surgery), since it may not be possible to visualize the angle or to properly pass the microcatheter.

Do not use the OMNI^® in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris.

Do not use the OMNI^® Surgical System in quadrants with previous MIGS implants.

Please refer to the full Instructions for Use, available HERE, for warnings, precautions, and adverse event information.

Warnings

1. Do not use in cases where there is insufficient visibility to properly see the iridocorneal angle. The following conditions may prohibit sufficient visualization required for safe and successful cannula and microcatheter placement: corneal edema, corneal haze, corneal opacity, or any other conditions that may inhibit gonioscopic view of the iridocorneal angle and intended cannula entry location.

2. Perform gonioscopy prior to taking a patient to surgery to exclude congenital anomalies of the iridocorneal angle, anterior segment dysgeneses, peripheral anterior synechiae (PAS), rubeosis, and any other angle abnormalities that could lead to improper placement of the cannula and microcatheter and pose a hazard.

3. Maintain direct microscopic or gonioscopic visualization of the cannula tip and microcatheter tip at all times during the procedure to facilitate advancement and to avoid inadvertently damaging intraocular structures, kinking the microcatheter or unintended tearing of trabecular meshwork.

4. The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. If intraocular pressure is not adequately maintained after surgery, the surgeon should initiate appropriate management of intraocular pressure.

Potential adverse events

Adverse events that may be reasonably associated with the use of the OMNI® System in the eye include, but are not limited to, the following: anterior chamber shallowing, severe, prolonged, or persistent intraocular inflammation, endophthalmitis or other ocular infection, aqueous misdirection, Descemet’s membrane tear or detachment, intracorneal hematoma, choroidal effusion, suprachoroidal hemorrhage, corneal decompensation, corneal injury, corneal edema or opacification, unintended trabeculotomy, cyclodialysis cleft, hyphema, hypopyon, hypotony, hypotony maculopathy, IOL dislocation, cataract formation, iris injury, tear, or iridodialysis, loss of vitreous, perforation of sclera, posterior capsular bag rupture, proliferative vitreoretinopathy, pupillary block, pupillary membrane formation, retinal detachment, retinal dialysis, retinal flap tears, secondary surgical intervention, including, but not limited to, glaucoma surgery, and vitreous hemorrhage. Federal (USA) law restricts this device to sale, distribution, or use by or on the order of a physician.